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Abstract 
The hypothalamic arcuate nucleus (ARC) and the area postrema (AP) represent targets for 
hormonal and metabolic signals involved in energy homeostasis, e.g. glucose, amylin, insulin, 
leptin, peptide YY (PYY), glucagon-like peptide 1 (GLP-1), and ghrelin. Orexigenic neuropeptide 
Y (NPY) expressing ARC neurons are activated by food deprivation and inhibited by feeding in a 
nutrient-dependent manner. PYY and leptin also reverse or prevent fasting-induced activation of the 
ARC. Interestingly, hypothalamic responses to fasting are blunted in different models of obesity 
(e.g. diet-induced or late-onset obesity). The AP also responds to feeding-related signals. The 
pancreatic hormone amylin acts via the AP to control energy intake. Amylin-sensitive AP neurons 
are also glucose-responsive. Furthermore diet-derived protein attenuates amylin responsiveness 
suggesting a modulation of AP sensitivity by macronutrient supply. This review gives an overview 
of the receptive function of the ARC and the AP to hormonal and nutritional stimuli involved in the 
control of energy balance and the possible implications in the context of obesity. Collectively, there 
is consistency between the neurophysiological actions of these stimuli and their effects on energy 
homeostasis under experimental conditions. However, surprisingly little progress has been made in 
the development of effective pharmacological approaches against obesity. A promising way to 
improve effectiveness involves combination treatments (e.g. amylin/leptin agonists). Hormonal 
alterations (e.g. GLP-1, PYY) are also considered to mediate body weight loss observed in obese 
patients receiving bariatric surgery. The effects of hormonal and nutritional signals and their 
interactions might hold the potential to develop poly-mechanistic therapeutic strategies against 
obesity.                
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Abbreviations: 
a-MSH a-melanocyte stimulating hormone 
ADP adenosine diphosphate 
 AgRP agouti-related peptide 
 AMPK adenosine monophosphate-activated protein kinase 
AP area postrema 
 APX area postrema lesion 
 ARC arcuate nucleus 
 ATP adenosine triphosphate 
 CCK cholecystokinin 
 cGMP cyclic guanosine monophosphate 
CPT1 carnitine palmitoyltransferase-1 
CTR calcitonin receptor 
 DIO diet-induced obesity 
 DR diet-resistant 
 FAS fatty acid synthase 
 GHS-R growth hormone secretagogue receptor  
GLP-1 glucagon-like peptide-1 
 GLP-1R glucagon-like peptide-1 receptor 
LOO late onset obesity 
 lPBN lateral parabrachial nucleus 
mTOR mammalian target of rapamycin  
NCD non-caloric diet 
 NPY neuropeptide tyrosine 
 NTS nucleus of the solitary tract 
OXM oxyntomodulin 
 POMC pro-opiomelanocortin 
 PVN paraventricular nucleus 
 PYY peptide tyrosine tyrosine 
 RAMP receptor activity modifying protein 
RYGB Roux-en-Y gastric bypass 
SDA subdiaphragmatic deafferentation 
STAT signal transducer and activator of transcription 
  
 4 
Introduction 
Driven by the search for therapeutic treatment strategies against obesity and associated metabolic 
disorders, considerable knowledge has accumulated about the control mechanisms involved in the 
maintenance of energy balance. The redundancy of control mechanisms, the capacity of these 
systems to compensate for pharmacological effects, and the existence of obesity-related hormonal 
insensitivities make it difficult to achieve sufficient therapeutic efficiency for the reduction of body 
weight over longer periods of time. Evidently, at least under non-laboratory conditions, so-called 
non-homeostatic factors (hedonic properties and availability of food, food preferences, social 
factors, eating habits, etc.) and central reward mechanisms override homeostatic hormonal and 
metabolic signals that are considered to reflect and to control the body’s energy status. 
In contrast to the currently available pharmacological treatment options, bariatric surgery (e.g. 
Roux-en-Y gastric bypass, RYGB) is very effective in reducing body weight and improving glucose 
homeostasis in patients with type II diabetes mellitus [1, 2]. Apparently bariatric surgery alters 
gastrointestinal physiology in a way that changes nutrient-induced gastrointestinal hormone 
responses, which presumably contribute to these therapeutic effects. Hence, the signaling 
mechanisms of the gut-brain axis and the interaction between its nutritional and hormonal feedback 
signals are not only essential for our understanding of the body’s energy homeostasis but also for 
the ultimate desire to develop pharmacological approaches against the obesity epidemic. Some of 
the hormones (e.g. GLP-1 and PYY) discussed in this review with regard to their central actions are 
presumed mediators of weight loss after bariatric surgery. While the exact mechanisms behind 
bariatric weight loss surgery and their potential to be targeted pharmacologically remain to be 
identified, there are other promising therapeutic approaches that are based on hormonal 
combination treatments. Both pre-clinical studies in obese rodents and clinical trials in humans have 
established a beneficial effect of combined treatment with the anorexigenic pancreatic hormone 
amylin with the fat-derived hormone leptin. Amylin treatment seems to reverse leptin insensitivity 
in obese subjects, in which amylin and leptin exert a synergistic action to reduce body weight [3, 4]. 
Brain circuits involved in the control of energy balance also function as fuel sensors responding to 
diet-derived macronutrients. Nutrients not only alter neuronal activity in feeding regulatory brain 
areas, they also modulate neuronal responsiveness to hormonal stimuli.  Two important brain sites 
that are targeted by hormonal and nutrient signals involved in the control of energy balance are the 
hypothalamic arcuate nucleus (ARC) and area postrema (AP) of the brainstem. The current review 
focuses on the receptive function of the ARC and the AP to feeding-related signals and alterations 
of neuronal responsiveness that are associated with obesity. It is beyond the scope of this review to 
describe similar hormone and nutrient-dependent signaling mechanisms in other brain areas that 
also contribute to the overall control of energy homeostasis.  
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The hypothalamic arcuate nucleus 
The ARC is considered as one of the most important hypothalamic target structures for blood-borne 
hormonal and metabolic factors involved in the regulation of food intake and energy homeostasis. 
The best-characterized hormone supposed to act via the ARC is the lipostatic and anorectic 
hormone leptin, a 16kDa protein that is secreted from white adipose tissue. Genetic deficiency of 
leptin or its receptor in rodents causes excessive food intake, body weight gain and an obese 
phenotype [5, 6]. Leptin acts via the ARC, which contains two functionally antagonistic populations 
of neurons with respect to the control of food intake. One population contains the orexigenic 
neuropeptides NPY and agouti gene-related peptide (AgRP) [7]. The other distinct population 
synthesizes the anorectic pro-opiomelanocortin (POMC) gene product α-melanocyte stimulating 
hormone  (α-MSH) [8]. Leptin up-regulates POMC neurons while it inhibits NPY/AgRP neurons in 
the ARC [9, 10]. Similar to leptin, insulin fulfills the criteria of an adiposity signal because 
circulating insulin levels increase in relation to body adiposity. Furthermore, insulin has access to 
the brain and it influences food intake and body weight in a similar way as leptin via the ARC [11].  
Catalyzed by the high importance of the ARC for body weight control and the failure of leptin 
therapy as an effective anti-obesity treatment because of leptin resistance [12] the scientific interest 
in other factors acting via the ARC and its downstream signaling pathways began to increase. The 
well-established concept that the ARC is targeted by the adiposity signals leptin and insulin has 
been extended by numerous studies demonstrating ARC-dependent actions of hormones, 
neuropeptides and metabolites that change dynamically according to the status of energy intake. 
Notably, leptin itself shows dynamic short-term changes as a function of food intake [13, 14].  
 
Ghrelin 
One of the hormones targeting the ARC is the orexigenic gastrointestinal hormone ghrelin [15]. 
Plasma levels of ghrelin are modulated by the nutritional state. During fasting and shortly before 
meals circulating ghrelin concentrations are elevated, while feeding or nutrient intake reduce blood 
ghrelin levels [16-18]. Various electrophysiological and immunohistological studies characterized 
ghrelin`s effects on neuronal activity of ARC neurons that have been suggested to represent target 
cells for ghrelin in the brain [19-22]. Ghrelin binds to the growth hormone secretagogue receptor 
(GHS-R) that is highly abundant in the ARC [23]. The GHS-R is predominantly expressed in NPY 
neurons (94% co-localization) while it is found in only 8% of POMC neurons [24]. Ghrelin exerts 
opposite effects to leptin on the activity of ARC neurons. Ghrelin or GHS-R agonists excite leptin-
inhibited NPY neurons via a direct postsynaptic effect [19, 25-27]. In addition to this action, ghrelin 
indirectly inhibits neurons of the lateral ARC, where POMC neurons are located [20, 28]. The 
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excitatory effect of ghrelin on ARC neurons and the NPYergic phenotype of these cells have been 
confirmed in vivo by immunohistochemical studies using c-Fos as a marker for neuronal activation 
[22, 29].  
Whether ghrelin can be considered a physiological signal in the control energy homeostasis has not 
yet been confirmed based on the general criteria that have been suggested to define a physiological 
relevance [30]. Due to the weak consequences of ghrelin antagonism for feeding behavior or body 
weight phenotype and because of the ineffectiveness of physiological ghrelin doses to produce 
feeding or body weight effects, the physiological relevance of ghrelin has not yet been fully 
established [31]. Due to the leptin counter-regulatory action of ghrelin, antagonism of ghrelin 
signaling has been proposed as a therapeutic approach against obesity. However, the role of ghrelin 
in the pathogenesis of obesity is not clear. Ghrelin levels in obese humans are lower than under 
normal weight conditions [32] limiting the usefulness and success of ghrelin antagonism as an anti-
obesity strategy [31]. Interestingly, weight loss in obese subjects seems to be associated with an 
increase in ghrelin levels suggesting that a blockade of ghrelin action might facilitate the body 
weight reducing effect of other therapeutic interventions [32]. Notably, there is cumulating 
evidence for a role of ghrelin in reward mechanisms that involve extra-hypothalamic pathways 
originating in the ventral tegmental area [33]. The potential of pharmacological ghrelin-dependent 
approaches with respect to this mechanism has not yet been sufficiently explored in clinical studies.  
 
PYY/GLP-1 
The two gut hormones PYY and GLP-1 act on ARC neurons. They have received special attention 
in the context of energy homeostasis and as potential targets for the treatment of overweight. Both 
hormones might contribute to weight loss after gastric bypass surgery because RYGB patients have 
increased GLP-1 and PYY levels and blockade of gastrointestinal hormone release (including GLP-
1 and PYY) by the somatostatin analogue octreotide led to increased appetite [34-36]. A specific 
role for PYY is suggested by absence of weight loss in PYY knockout mice subjected to 
gastrointestinal bypass surgery [37].  
PYY and PYY(3-36) are two biologically active peptides arising from endocrine L cells of the 
ileum and colon in response to food intake [38]. While PYY binds to several subtypes of Y 
receptors, PYY(3-36) exhibits relative specificity for the Y2 receptor [39]. Both PYY isoforms 
inhibit food intake after peripheral administration; but PYY(3-36) appears to be more potent 
possibly due to its specificity to the Y2 receptor that is decisive for the anorexigenic response [40, 
41]. However, the minimal doses that were required to suppress food intake in these studies were 
supraphysiological when compared to meal-induced changes of total PPY blood levels. Therefore, 
the question whether PYY(3-36) acts as a physiological satiating signal is controversial. Direct site-
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specific injections of PYY(3-36) identified the ARC as possible central target structure [42]. With 
respect to the electrophysiological effects of PYY(3-36) in the ARC, conflicting data exist in 
literature. In mice, PYY(3-36) has been demonstrated to indirectly (presynaptically) excite 
phenotypically identified POMC neurons [42], while another electrophysiological study 
demonstrated direct postsynaptic inhibitions in POMC neurons of mice [43]. Among others, the 
reasons for these seemingly contradictory findings have not yet been identified, but might be related 
to experimental and technical differences concerning the slice preparation and selection of cells 
[43]. In rats, full length PYY exerts direct inhibitory effects on ghrelin-exited ARC neurons (figure 
1) suggesting that the NPYergic system is also affected by PYY signaling [44]. This is consistent 
with the demonstration that PYY(3-36) inhibits NPY release from ARC explants in addition to 
stimulating a α-MSH response [42].  
Basal and postprandial PYY(3-36) levels are decreased in obese humans and rodents [45]. The 
absence of PYY(3-36) resistance in obese subjects is in favor of using PPY agonists as anti-obesity 
drugs. Chronic peripheral administration of PYY(3-36) decreases body weight in different species 
including rhesus macaques [42, 46, 47]. Whether PYY agonists can be therapeutically used in 
humans to reduce body weight awaits further evaluation. Interestingly, PYY seems to synergize 
with other hormones or hormone agonists affecting the control of energy balance and glucose 
homeostasis, including the GLP-1 agonist exendin-4 and the pancreatic hormone amylin [48, 49]. 
The neuronal correlates of these synergies are unknown. 
 
Similar to PYY, GLP-1 is released in response to food intake from gastrointestinal L-cells [50, 51]. 
GLP-1 plays an important role in glucose homeostasis (incretin) and gastrointestinal function [52]. 
In addition to its peripheral expression, GLP-1 is a neuropeptide expressed in a discrete population 
of enteroceptive neurons of located in the brainstem [53]. It binds to the GLP-1 receptor (GLP-1R) 
that is also activated by the agonist exendin-4, a peptide that has been isolated from the saliva of the 
lizard Heloderma suspectum. The truncated form of exendin(9-39) (also termed exendin-9) acts as a 
competitive antagonist at the GLP-1R. The ARC, and other hypothalamic and brainstem structures, 
including the paraventricular nucleus (PVN) and the AP, show high GLP-1R expression [54, 55]. 
Central and peripheral injection GLP-1R agonists decrease food intake in rodents [56-59]. 
Furthermore, numerous studies have demonstrated a GLP-1-mediated reduction in energy intake in 
humans [60]. Similar to ghrelin and PYY, it has not yet been confirmed that endogenous GLP-1 
physiologically controls food intake.  
The neuronal mechanisms mediating the action of GLP-1 on food intake have not yet been clearly 
identified, which might be due to the fact that different pathways seem to be activated depending on 
the experimental conditions, particularly the route of administration and the potency of the stimulus. 
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While subdiaphragmatic deafferentation (SDA) blocked the anorexigenic effect of hepatic portal 
vein GLP-1 infusion, SDA did not blunt the feeding suppressive effect of GLP-1 infused into the 
vena cava [61]. In contrast, the effect of the long-acting GLP-1 agonist exendin-4 was not blocked 
in SDA rats [62]. There is some evidence that the ARC represents a target site not only for GLP-1 
but also for the structurally related hormone oxyntomodulin (OXM), which is co-secreted with 
GLP-1 and exerts an anorexigenic effect via the GLP-1R after central injection [63, 64]. GLP-1R 
activation by intra-arcuate injection of OXM decreased food intake and the OXM-mediated 
suppression of intraperitoneal OXM administration was blocked by injection of the GLP-1R 
antagonist exendin(9-39) [58]. Another study did not observe a feeding suppressive effect after 
intra-arcuate GLP-1 injection, but hepatic glucose production was reduced under these conditions 
[65]. However, GLP-1 consistently reduced feeding after site-specific injection into the PVN [65, 
66].  
The effects of GLP-1 and OXM on neuronal activity in the ARC are similar. In rats, both hormones 
induced excitatory responses in ghrelin-inhibited cells (see example in figure 2) suggesting a 
stimulation of POMC signaling, which is consistent with the high expression of the GLP-1R in 
POMC neurons [65]. GLP-1 and OXM induced heterogeneous excitatory and inhibitory effects in 
ghrelin-excited ARC neurons, but the functional and neurochemical phenotype of these cells has 
not yet been identified. The absence of GLP-1R expression in NPY neurons seems to exclude the 
NPY system as a primary target for GLP-1 in the ARC. Despite the existing in vivo and in vitro 
evidence for a potential role of ARC-dependent GLP-1 signaling in energy and glucose homeostasis 
further support for a physiological role of endogenous GLP-1R ligands acting via hypothalamic 
circuits needs to be established. Although beneficial effects on body weight have been reported for 
anti-diabetic GLP-1 agonists [67-69], moderate effectiveness and undesired side effects limit the 
potential of these drugs at least as a mono-therapy against obesity.  
 
Feeding and nutrient-related effects on neuronal function 
Numerous studies have confirmed the reciprocal regulation of NPY and POMC gene expression in 
response to alterations in energy intake [70]. Fasting not only leads to alterations in neuropeptide 
expression but also to changes in neuronal activity. Food deprivation for 24h elicits an activation of 
ARC neurons in mice as reflected by an increase in c-Fos expression [71-73]. Refeeding of 12h 
food-deprived mice completely reverses the fasting-induced ARC activation indicating that feeding-
related signals exert a strong inhibitory effect on ARC neurons that are activated under negative 
energy balance [44, 74]. Hence, ARC neurons appear to respond to negative and positive changes in 
energy intake. As demonstrated by phenotyping studies, fasting-induced ARC activation 
specifically occurs in NPY neurons, but in not POMC neurons under these conditions [74, 75]. 
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While this observation suggests increased hypothalamic NPY signaling as a result of fasting, it does 
not exclude a parallel inhibition of POMC neurons in the ARC. The induction of a fasting-induced 
ARC activation has also been demonstrated in rats, although considerably longer periods of food 
deprivation (3 days) are typically required for an immunohistochemically detectable response in 
this species, at least when c-Fos is used as a marker. Interestingly, there seems to be a shift of 
neuronal activation from the NPY system in the fasted state to the melanocortin system following 
refeeding [76, 77]. This response is consistent with the function of the NPY system to promote 
energy intake under negative energy balance and with the counter-regulatory function of the POMC 
system to limit energy intake.    
Feeding of palatable non-caloric diet (NCD; vanilla-flavored cellulose) with or without selective 
nutrient supplementation has proven to be a useful approach to explore the role of diet-derived 
nutrients in feeding-related modulation of neuronal ARC activity. Mice receiving NCD for 12h 
instead of standard chow exhibit a strong c-Fos expression in the ARC that is only slightly lower 
than in 12h fasted animals [74]. The same is true for fasted mice that were refed with NCD. 
Therefore, nutrient-independent stimuli associated with feeding activity (e.g. gustatory, 
oropharyngeal cues, gastric distension) appear to exert a minor but significant influence on the ARC 
because they only weakly counteract the stimulation of ARC activation triggered by short term 
caloric deprivation. When refeeding with NCD was selectively supplemented with each of the 
different macronutrients (carbohydrates, protein or fat), a stronger reversal of fasting-induced ARC 
activation was observed than that following refeeding with non-supplemented NCD [74]. When the 
intake of each nutrient was matched to specific nutrient intake of chow-fed animals, the 
carbohydrates were more effective than protein and fat. However, increasing the protein content in 
the diet or refeeding with pure fat (lard) resulted in a similar reversal of fasting-induced c-Fos 
expression as observed for refeeding with carbohydrate. Therefore, the relative contribution of each 
macronutrient to the inhibition of ARC activity in this experimental setting appeared to depend on 
the amount of intake. Whether isocaloric intakes of the different macronutrients are equipotent to 
reverse fasting-induced ARC activation has not yet been investigated.         
The mechanism underlying the fasting and feeding-related effects on neuronal activity in the ARC 
are likely to involve direct effects of metabolites but also indirect actions mediated by 
gastrointestinal hormones. ARC neurons have been shown to respond to glucose in excitatory and 
inhibitory ways [78]. Phenotypically identified NPY neurons of mice and rats decrease their firing 
rate with increasing glucose concentrations (glucose-inhibited cells) [79, 80]. Conversely, POMC 
neurons have been demonstrated to be glucose-excited because they decrease their discharge rate 
when the extracellular glucose concentration is decreased [81, 82]. The intracellular mechanisms 
transducing changes in the glucose concentration into altered neuronal activity are well understood 
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for glucose-excited neurons, while the molecular correlates of inhibitory glucose signaling are less 
clear. Glucose sensitivity in glucose-excited neurons has obvious parallels to glucose 
responsiveness of pancreatic beta-cells, in which glucose metabolism leads to increased ATP:APD 
ratios. As a consequence ATP induces a closure of the Kir6.2 pore-forming subunit of the ATP-
sensitive potassium channel, leading to a depolarization of the cell. Genetic manipulations that 
cause a loss of function of Kir6.2 subunit are associated with a loss of glucose responsiveness in 
hypothalamic neurons, including POMC neurons of the ARC [82, 83]. Although the ATP-sensitive 
potassium channel is required for the glucose sensitivity of glucose-excited neurons, it is also 
expressed in glucose-insensitive cells suggesting that other molecular transducers are decisive for 
neuronal glucose responsiveness. One of these transducers is the enzyme glucokinase, the rate-
limiting enzyme for glucose metabolism in glucose sensitive neurons [84]. Another enzyme that 
seems to function as a master switch for intracellular metabolic pathways including glucose 
metabolism is the enzyme adenosine monophosphate-activated protein kinase (AMPK). AMPK 
responds to changes in the ADP:ATP ratio and induces counter-regulatory metabolic responses via 
a variety of downstream targets [85]. Hypothalamic AMPK activity in the ARC and other 
hypothalamic structures is not only inhibited by leptin and insulin, but also by refeeding in fasted 
mice and by intraperitoneal and intracerebroventricular glucose administration [86]. Genetic 
manipulation that results in constitutive hypothalamic AMPK activity was associated increased 
body weight gain, while reduced AMPK activity resulted in reduced body weight. These effects 
were partly attributed to changes in food intake [86]. Genetic disruption of AMPK in POMC and 
NPY neurons was paralleled by a loss of glucose responsiveness of these cells in the ARC 
supporting of a role of AMPK in glucose sensing [81]. In line with the well-established glucose 
sensitivity of ARC neurons, an increase in circulating glucose after intrapritoneal glucose 
administration reversed the fasting-induced ARC activation to a similar degree as refeeding [87]. 
These studies do not exclude indirect hormonal or vagal afferent signaling mechanisms that might 
be engaged in parallel to a direct action of glucose on ARC neurons.  
Not only glucose but also hypothalamic fatty acid signaling contributes to the control of energy 
balance and glucose homeostasis because intracerebroventicular infusion of oleic acid inhibits food 
intake and hepatic glucose production [88, 89]. Besides other hypothalamic structures, the ARC has 
been identified as a fatty acid responsive area [90]. Lipid sensitivity has been demonstrated for 
POMC neurons that were inhibited by oleic acid [91]. In analogy to the importance of intracellular 
glucose metabolism, intracellular lipid metabolism has been linked to altered neuronal function and 
to changes in food intake and body weight. Pharmacological blockade fatty acid synthase (FAS) 
pathway by central or peripheral injection of the FAS inhibitor C75 inhibited feeding and reduced 
body weight in mice [92]. Among other hypothalamic sites, FAS is expressed in NPY neurons of 
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the ARC [93]. Peripherally applied C75 prevented the fasting induced c-Fos expression in the 
medial ARC and in hypothalamic downstream targets of the ARC supporting a role of lipid 
signaling in fasting-induced ARC activation [94]. Different intracellular mechanisms have been 
proposed to mediate the effects of FAS inhibition on energy homeostasis. These mechanisms 
include an increase in the FAS substrate malonyl CoA, which represents an intracellular metabolic 
signal inhibiting food intake and body weight. This view is consistent with the development of 
obesity and increased food intake when malonyl CoA degradation in the mediobasal hypothalamus 
is enhanced by overexpression of the enzyme malonyl CoA decarboxylase [95]. A regulatory 
function for cellular lipid sensing has also been postulated for the enzyme carnitine 
palmitoyltransferase-1 (CPT1) that controls long chain fatty acid transport into the mitochondria. 
Pharmacological or genetic inhibition of hypothamalic CPT1 reduced food intake and glucose 
production [96]. Despite the cumulating evidence for a role of hypothalamic lipid sensing further 
confirmation is required for the physiological relevance of these processes in the context of feeding-
related or metabolically induced changes in circulating mediators involved in lipid signaling.  
Similar to lipid signaling a role of hypothalamic amino acid signaling in the control of food intake 
and body weight has emerged. The serine-threonine kinase mammalian target of rapamycin 
(mTOR) functions as nutrient sensor implicated in cell growth and proliferation [97]. Particularly 
branched amino acids such as leucine activate the mTOR pathway. Components of the mTOR 
pathway have been detected in 90% and 45% of ARC NPY and POMC neurons, respectively [98]. 
In analogy to the changes of neuronal activity in the ARC as a result of fasting and refeeding, 
activity of the mTOR pathway in the ARC is down-regulated in the fasted state while it increases in 
response to refeeding. Both, intracerebroventricular and site-specific injection of leucine into the 
mediobasal hypothalamus inhibited food intake [98, 99]. POMC neurons of the ARC increase their 
electrical activity in response to stimulation with leucine, which is consistent with in vivo studies 
demonstrating a melanocortin receptor involvement in the anorexigenic effect of mediobasal 
hypothalamic leucin injection [99].  
Fasting and the ingestion of each of the single macronutrients lead to hormonal responses adjusting 
energy homeostasis and gastrointestinal function to the metabolic and digestive requirements of the 
body. Some attempts have been made to explore the involvement of hormones in the feeding-
related changes in ARC activity. Based on the increase in ghrelin levels under fasting conditions 
ghrelin might contribute to the fasting-induced ARC activation in mice. In rats, neutralization of 
ghrelin by a site-specific injection of anti-ghrelin immunglobulins into the ARC attenuated food 
intake in fasted animals during refeeding [100]. An alternative approach to neutralize ghrelin is the 
use of an L-RNA-based hormone antagonist, a so-called Spiegelmer, that specifically binds and 
inactivates the bioactive form of ghrelin [101, 102]. Due to its long-lasting action a single 
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intravenous infusion of the anti-ghrelin Spiegelmer NOX-B11-3 blocked the c-Fos response in the 
ARC of ad libitum fed mice induced by exogenous ghrelin injected peripherally 12h after 
administration of the antagonist [21]. In the same study, ghrelin antagonism did not significantly 
attenuate the fasting-induced c-Fos response in the ARC suggesting that endogenous ghrelin is not 
necessary for the activation of the ARC under these experimental conditions. 
Among the feeding-related hormones that are likely to act via the ARC ghrelin is the only one that 
increases during fasting. Not only increases but also decreases in hormone levels are likely to 
reflect alterations in energy homeostasis and metabolism. One experimental approach to investigate 
this consists in the compensation of decreased hormone levels by exogenous administration of the 
respective hormone. Superimposed to the well-described differences in leptin levels related to body 
adiposity, leptin plasma levels decrease considerably (5-fold) in fasted vs. ad libitum fed lean mice 
[74]. Preventing the fasting-induced decrease in leptin by repeated low dose leptin injections during 
the fasting period markedly attenuated the c-Fos expression of in the ARC of food-deprived mice 
(figure 4) [103]. Despite the limitation of this approach to precisely mimic physiological leptin 
levels by exogenous leptin administration, this finding supports a contribution of decreased leptin 
signaling to fasting-induced ARC activation. Studies in leptin deficient ob/ob mice seem to 
complement these findings because fasting-induced ARC activation is exaggerated in ob/ob mice 
compared to wild-type littermates [103]. Together these studies underscore that leptin signaling has 
an important impact on the ARC in the context of feeding-related modulation of ARC neurons. 
Using the fasting/refeeding paradigm the possible involvement of other hormones in feeding-related 
changes of ARC activity have been studied. Similar to the ineffectiveness of an acute leptin 
treatment to reverse fasting-induced ARC activation, insulin did not attenuate c-Fos expression in 
fasted animals regardless of whether a glucose-lowering dose of insulin was used or a dose that did 
not produce a reduction in blood glucose [74]. Besides insulin the anorexigenic hormones PYY, 
amylin and cholecystokinin (CCK) were tested for their ability to reverse fasting-induced c-Fos 
expression in the ARC. Only PPY, but not amylin or CCK attenuated the stimulation of ARC 
neurons in food-deprived mice [74, 104]. The lack of effectiveness was probably not due to 
ineffective doses because in the same animals both amylin and CCK elicited c-Fos expression in the 
AP and the NTS, respectively. Since amylin and CCK primarily act via the brainstem (see below) 
and because the ARC is considered as a target site for PYY, these finding are consistent with the 
presumed central signaling mechanisms for these hormones. Despite the failure of CCK and amylin 
to reverse fasting-induced ARC activation, at least CCK partially prevented ghrelin-induced c-Fos 
expression in the ARC in ad libitum fed mice [74] indicating some CCK-dependent inhibitory input 
to the ARC. Collectively, these findings suggest diverse roles for the investigated hormones in 
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feeding-related changes of neuronal function in the ARC. However, the use of knockout models or 
specific hormone antagonists is required to confirm the relevance of endogenous hormone actions.     
 
Altered neuronal ARC responses in obese rodent models 
Obesity is associated with hormonal and metabolic perturbations, including hyperleptinemia, 
hyperinsulinemia, leptin and insulin resistance, dyslipidemia and hyperglycemia and others [12, 
105, 106]. In rodent models of diet-induced obesity (DIO) neuronal to responsiveness of ARC 
neurons to leptin is disrupted. DIO mice show a reduced phosphorylation of the signal transducer 
and activator of transcription 3 (STAT3), a marker for leptin receptor activation [107, 108]. 
Furthermore, the leptin-dependent release of NPY and α-MSH [109] is decreased. As recently 
demonstrated, obesity also seems to be associated with ghrelin resistance in the ARC because 
peripheral or central ghrelin injection did not induce food intake and ARC activation in DIO mice 
[110]. Moreover, ghrelin failed to induce the release of NPY and AgRP in hypothalamic explants 
from DIO mice in this study. Not only hormonal resistance but also impaired responsiveness of the 
ARC to metabolic stimuli has been described [111]. 
It has been demonstrated in different obesity models that obese mice show blunted neuronal 
responses of the ARC to alterations in energy intake. Age-related obese (late onset obesity, LOO) 
and DIO mice show completely absent or a strongly attenuated fasting-induced activation of NPY 
neurons in the ARC depending on the duration of food deprivation (12h or 24h, respectively). The 
blunted responses in these animals were not due to age per se or due to high-fat diet feeding 
because age-matched controls and diet-resistant lean controls (DR) showed intense fasting-induced 
c-Fos responses in the ARC [103, 112]. The absence of fasting-induced ARC activation was 
associated with the absence of refeeding hyperphagia that only occurred in lean mice after fasting 
but not in LOO mice. The blunted ARC activation in these hyperleptinemic obesity models 
contrasts with the exaggerated fasting response in the ARC of obese leptin deficient ob/ob mice 
[112]. Measurements of metabolic (blood glucose and lipids) and hormonal parameters (insulin, 
ghrelin, leptin) were conducted in fasted and ad libitum fed obese mice and in respective lean 
controls [103, 112]. Among these parameters, the only factor that consistently predicted the altered 
neuronal responses across the different obesity models was leptin because neuronal ARC activation 
is enhanced under leptin deficiency, prevented by exogenous leptin and blunted under 
hyperleptinemia. However, the idea that obesity-related hyperleptinemia prevents the response of 
the ARC to fasting is challenged by well-described leptin resistance in hyperleptinemic obesity. 
Factors that limit central effectiveness of circulating leptin involve reduced transport across the 
blood-brain barrier, increased intracellular inhibition of leptin-signaling and reduced leptin receptor 
expression. Each of these factors is affected by feeding in a way that promotes leptin 
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responsiveness under fasting conditions. Fasting increases the rate of leptin transport into the brain 
[113, 114], reduces intracellular leptin-antagonistic signaling [115, 116] and increases leptin 
receptor expression [117] and leptin binding to the receptor [118]. Hence, leptin responsiveness is 
dynamic and linked to the feeding status. In line with this assumption, fasting not only increases the 
leptin-induced STAT3 phosphorylation in lean mice but also in LOO mice that did not show a 
significant pSTAT3 response in the ad libitum fed state [103]. Consequently, the combination of 
increased leptin levels and increased leptin responsiveness might prevent the activation of ARC 
neurons under negative energy balance. Together these findings suggest that dynamic changes in 
leptin sensitivity under hyperleptinemia might interfere with the receptive function of the ARC for 
stimuli reflecting short-term excursions in energy intake. 
 
The area postrema 
The AP is a sensory circumventricular organ located in the dorsal vagal complex of the brainstem. 
Due to the lack of a functional blood-brain barrier AP neurons can be reached by humoral factors 
including peptide hormones, that do not passively cross the blood-brain barrier is other areas of the 
brain. The AP is neuronally interconnected with structures of the visceral enteroceptive neuroaxis 
including the nucleus of the solitary tract (NTS) and the lateral parabrachial nucleus (lPBN) [119]. 
Among other neuronal efferents the AP also projects to the dorsal motor nucleus of the vagus that 
controls visceral motor functions. The AP plays an important protective role as a so-called 
chemoreceptor trigger zone that mediates aversive and emetic responses induced by noxious or 
toxic stimuli. This function is for example reflected by the absence of lithium chloride induced taste 
aversion after ablation of the AP lesioned in rats [120].  
Observations from AP lesion studies suggested an AP involvement in the control of food intake and 
body weight. AP-lesioned (APX) rats are hypophagic and show lower body weight compared to 
sham-lesions animals, although they over-consume highly palatable food [121, 122]. Furthermore, 
AP lesion leads to loss of hypoglycemic or glucoprivic feeding responses induced by insulin, 2-
deoxy-glucose or 5-thio-glucose [121, 123], suggesting a role of the AP in central nervous glucose 
sensing. 
 
AP-mediated effects of amylin on food intake     
The AP has been identified as a target structure for the anorexigenic hormone amylin, which is 
widely accepted to contribute to the physiological control of food intake. Amylin is co-secreted 
with insulin from pancreatic beta cells in response to meal-related stimuli [124]. Amylin reduces 
food intake at near physiological doses via a reduction of meal size [125-127]. Amylin antagonism 
not only blocks the anorexigenic effect of exogenous amylin but also increases food intake, 
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supporting a physiological role of endogenous amylin in energy intake [128]. Numerous studies 
provided evidence that the AP mediates amylin’s suppressive effect on food intake. While vagal 
afferents are not required for amylin’s anorexigenic action [129], AP lesion blocks feeding 
inhibitory action of amylin [130-132].  
The effects of amylin on neuronal function in the AP and the transmission of amylin signaling to 
other brain structures involved in the control of energy homeostasis are well established. The 
amylin receptor consists of a functional complex of the calcitonin receptor (CTR) and so-called 
receptor activity modifying proteins  (RAMP1 and RAMP3) [133]. The CTR is densely expressed 
in the AP [134], where also RAMP3 gene expression has been described [135]. In 
electrophysiological studies, amylin exerted strong excitatory effects in 44% of the recorded 
spontaneously active AP neurons [136]. These effects were blocked by the amylin receptor 
antagonist AC187 and appeared to be mediated by the intracellular second messenger cyclic 
guanosine monophosphate (cGMP). The excitatory action of amylin on AP neurons is in line with 
studies demonstrating an amylin-induced c-Fos expression in the AP [136, 137]. Not only 
exogenous but also feeding-related endogenous amylin activates AP neurons because refeeding of 
fasted rats triggered a c-Fos response in the AP that was attenuated by amylin antagonism [138]. 
About 50% of neurons showing amylin-induced c-Fos are noradrenergic and specific neurotoxic 
lesion of these cells blunted amylin’s feeding inhibitory action [139]. 
 
Interaction of amylin and nutrient signaling 
Glucose 
In support of the abovementioned evidence for a role of the AP as central glucose sensor, 
electrophysiological studies identified glucose-responsive neurons in the AP [140]. These studies 
were extended by the demonstration that amylin sensitive neurons in the AP are specifically excited 
by glucose (figure 5), whereas amylin insensitive neurons are unresponsive to changes in the 
ambient glucose concentration [141]. Based on the importance of amylin sensitive AP neurons for 
the physiological control of feeding behavior these findings further support a role of the AP in the 
metabolic control of food intake. The AP is not the only glucose sensitive structure in the 
brainstem, but it is located in a brainstem area where local injection of 5-thio-glucose induced the 
strongest glucoprivic feeding responses [142]. 
The glucose sensitivity of the AP has also been postulated as protective mechanism against 
excursions in blood glucose values. Hypoglycemia induces a counter-regulatory increase in the rate 
of gastric emptying [143] that compensates the decreased blood glucose via increased 
gastrointestinal nutrient absorption. This mechanism interferes with hormonal and pharmacological 
effects that delay gastric emptying because glucose appears to be a permissive factor. Amylin 
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potently inhibits gastric emptying via an AP-dependent action, which is overridden by 
hypoglycemia [144]. Our group recently demonstrated a similar permissive effect of glucose for 
amylin’s feeding suppressive effect because amylin failed to significantly inhibit feeding under 
hypoglycemic conditions (Neuner-Boyle, C.; unpublished observations). The inhibitory effect of the 
amylin agonist pramlintide on gastric emptying is an important therapeutic mechanism to lower 
postprandial glucose levels in diabetic patients. Since treatment-induced hypoglycemia is a severe 
risk in diabetic patients, the permissive effect of glucose on gastric emptying is considered as a fail-
safe mechanism that overrides the anti-diabetic action of amylin agonism under hypoglycemic 
conditions (see [145, 146] for review).  
 
Protein 
Amylin’s satiating and effect and amylin-induced AP activation are modulated by diet-derived 
macronutrients, in particular by protein. An influence of diet-derived nutrients on amylin signaling 
was inferred from the observation that amylin-induced activation of the AP is stronger in fasted vs. 
ad libitum fed rats and also in rats that received nutrient-deficient NCD [147]. Selective 
supplementation of NCD with protein but not with glucose or fat strongly attenuated the amylin-
induced AP activation suggesting that protein counteracts anorexigenic amylin signaling. In light of 
the well-established satiating action of protein this assumption appeared unexpected, but it was 
confirmed by feeding studies in which amylin failed to inhibit protein supplemented NCD (figure 6) 
[147]. The inhibitory effect of diet-derived protein on amylin action has been corroborated by 
immunohistological and feeding studies using isocaloric diets of different protein content. Amylin 
more potently decreased intake of 1% and 8% protein chow than standard chow containing 18% 
protein. Similarly amylin-induced c-Fos expression was higher in rats receiving less protein [148]. 
These effects were not secondary to altered caloric intake that was similar across the experimental 
groups. While blood glucose levels were also similar, blood amino acid levels decreased in rats fed 
low protein diet suggesting that circulating amino acids might contribute the protein-dependent 
attenuation of amylin-induced AP activation. Pre-treatment of rats with an intraperitoneal 
administration of a mixed amino acid solution also attenuated amylin’s c-Fos response in the AP, 
which supports this hypothesis [148]. However, the exact neuronal mechanism underlying the 
protein-dependent modulation of amylin signaling remains to be identified. The relationship 
between reduced amylin-responsiveness and protein intake might bear both physiological and 
therapeutic implications. Amylin’s function in the control of nutrient and energy intake might be 
adapted to the nutrient composition of the diet. At least under undisturbed energy homeostasis 
protein is metabolically less important than carbohydrate or fat, which might suggest that amylin’s 
contribution to the overall control of energy intake is stronger when the intake of protein relative to 
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glucose or fat is low. Another mutually not exclusive implication might consist in an AP-sensitizing 
effect produced by short term reduction of food intake or food availability in a protein-dependent 
manner, pre-adapting AP responsiveness to a higher level in the pre-prandial state before meal 
onset. In addition to the possible physiological relevance, the effectiveness of pharmacological 
approaches based on amylin agonism might be influenced in a nutrient-dependent way. 
 
Fat 
There is not much experimental evidence for a role of the AP in lipid sensing. Although lipoprivic 
feeding induced by the fatty acid oxidation inhibitor mercaptoacetate is blunted in rats after 
AP/NTS lesion, this effect has been attributed to the destruction of vagal terminal fields in the NTS 
[149]. Accordingly, lipoprivic feeding is also blocked in vagotomized rats, confirming a mediation 
of vagal afferent signals [149]. Similarly, c-Fos expression in the AP/NTS region after 
intraduodenal lipid infusion is attenuated by capsaicin-induced destruction of vagal afferents and by 
CCK receptor antagonism. The latter finding indicates an indirect effect of intestinal lipid sensing 
via CCK-mediated activation the vagal afferents signaling [150]. It is reasonable to assume that 
amylin signaling and vagally transmitted lipid/CCK dedendent signals converge at the level of the 
AP/NTS region. Furthermore, the existence of a satiogenic synergy between amylin and CCK [151] 
might imply that lipid dependent signals indirectly enhance amylin’s feeding suppressive effect via 
a CCK-dependent action. Unlike the development of hormonal resistance to leptin and insulin as a 
consequence of prolonged high fat diet feeding, neither short-term nor long-term high-fat diet 
feeding leads to amylin resistance at least when amylin’s inhibitory action on food intake is used as 
an index of amylin responsiveness [152].  
 
Hormonal interactions involving AP and brainstem mechanisms 
The dorsal vagal complex is a site of convergence for vagal and blood-borne signals controlling 
food intake. Brainstem structures including amylin sensitive sites are reciprocally interconnected 
with hypothalamic and extra-hypothalamic areas involved in energy homeostasis [153]. For some 
hormones known to act via the brainstem synergistic effects have been described, although the 
existence of a synergy is not always based on equal criteria in the literature. Synergy is often 
inferred from the observation that the effect of two combined stimuli is higher than the sum of the 
effects when each stimulus is applied alone. Sophisticated statistical models (e.g. isobolographic 
analysis) have been used to detect and describe synergistic actions. Several synergistic effects have 
been demonstrated for amylin in combination with other hormones [154]. In addition to the synergy 
between amylin and CCK mentioned above, there is a synergistic effect of amylin and leptin to 
reduce body weight in obese and lean subjects [3, 4]. Several neuronal mechanisms have been 
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associated with the synergy between amylin and leptin. Amylin seems to enhance neuronal leptin 
responsiveness as reflected by the reversal of the blunted pSTAT3 response to leptin in the 
ventromedial hypothalamus. Amylin affects leptin signaling in the brainstem because amylin 
knockout mice tend to show reduced leptin-induced STAT3 phosphorylation in the NTS, and pre-
treating leptin-resistant DIO rats with amylin increased leptin-dependent pSTAT3 signaling in the 
AP [3, 4]. 
Anorexigenic synergy has also been reported for amylin and PYY(3-36), whereas body weight 
reduction was additive [49]. The neuronal correlate of this anorexiogenic synergy has not yet been 
identified. While the AP was not required for PYY(3-36)-induced suppression of feeding in one 
study [155, 156], another study suggested an involvement of the AP in the PYY-dependent effects 
on gastric acid secretion [157]. Binding sites for PYY of the Y receptor family are abundant in the 
AP [158-160]. Interestingly, a dose of full length PYY that did not trigger a c-Fos response in the 
AP alone, increased amylin-induced c-Fos expression in the AP [104] suggesting a possible 
interaction between amylin and PYY in the AP. 
A recent study conducted in non-human primates demonstrated anorexigenic synergy between the 
potent amylin receptor agonist salmon calcitonin and the GLP-1R agonist exendin-4 [161]. The 
mechanism underlying this synergy also remains to be identified. There is evidence that GLP-1 
inhibits feeding via an AP-dependent effect after hepatic portal vein infusion [162]. However, the 
anorexigenic effect of exendin-4 is not blocked in APX rats [163]. Although amylin and GLP-1 
activate AP neurons, these hormones seem to have different target cells in the AP. Similar to the 
aversive stimulus lithium chloride, GLP-1 and exendin-4 almost exclusively activate AP neurons 
that do not express the CTR, which is considered as a marker for the primary target cells for amylin 
in the AP [148]. The functional implication of this dissociation has not yet been specifically 
investigated. GLP-1R-mediated activation of the AP has been linked to the induction of aversion 
[164]. Therefore it is particularly important to exclude aversive mechanisms in approaches based on 
GLP-1R activation.     
 
Conclusions 
Extensive evidence has accumulated demonstrating that the ARC and the AP are responsive to 
hormonal and nutrient-related signals involved in the homeostatic feedback control of energy 
homeostasis. Overall, the neurophysiological effects that have been described by a multitude of 
different in vivo and in vitro approaches are consistent with the effects of these signals on food 
intake, body weight or metabolism. However, for many of the discussed mechanisms the 
physiological relevance remains to be confirmed. Even when physiological relevance is established 
(e.g. amylin) or postulated (ghrelin, PYY, GLP-1) the predictive value of these physiological 
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mechanisms for the effectiveness of mono-therapeutic anti-obesity approaches targeting these 
mechanisms appears to be weak. Nevertheless, the impressive effectiveness of bariatric surgery 
suggests the existence of signaling mechanisms that potently reduce body weight and improve 
metabolic disorders without being compensated by the body. Obviously, the interaction between the 
different feedback signals has been underestimated, which is reflected by the promising 
improvements in the therapeutic outcome of combination treatments. The concept of the 
homeostatic feedback control of energy homeostasis needs to be integrated into the increasing 
knowledge about the non-homeostatic controls affecting energy balance.  
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Figure 1: Continuous rate meter recording of a spontaneously active neuron from the medial arcuate 
nucleus of the rat. Consecutive superfusions of ghrelin and the anorectic hormone peptide Y (PYY) 
at the indicated times caused opposite effects on neuronal activity. While ghrelin induced a strong 
excitatory response, PYY effectively decreased the discharge rate. Reproduced with permission 
(published in Riediger T. et al, Neuroendocrinology 2004;79:317-326).  
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Figure 2: Representative recording showing the excitatory effect of glucagon-like peptide-1 (GLP-
1) on a ghrelin-inhibited neuron of the arcuate nucleus. Published in Riediger T. et al., Am J Physiol 
Regul Integr Comp Physiol 2010;298:R1061-R1067. 
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Figure 3: Refeeding with chow completely reversed the fasting-induced c-Fos expression in the 
arcuate nucleus (ARC). Representative ARC sections immunostained for c-Fos of 14-h fasted (A), 
chow-refed (B) and ad libitum chow-fed (C) mice. Bar charts show the quantitative results of c-Fos 
expression (D). a,b Different letters indicate significant differences between groups (P < 0.05). 3V: 
3rd ventricle. Scale bar: 100 µm. Published in Becskei C. et al., Am J Physiol Regul Integr Comp 
Physiol 2009;297:R100-R110. 
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Figure 4: Effect of exogenous leptin-induced hyperleptinemia during fasting on arcuate nucleus 
(ARC) activation in lean mice. Representative ARC sections immunostained for c-Fos of young 
lean mice treated with saline or leptin every 3 h during a 14-h food-deprivation period. Leptin 
treatment significantly increased the leptin plasma concentration and attenuated the fasting-induced 
c-Fos expression in the ARC (**P < 0.01 for both effects). 3V: 3rd ventricle. Scale bar: 100 µm. 
Published in Becskei C. et al., Am J Physiol Regul Integr Comp Physiol 2010;299:R632-R641. 
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Figure 5: Co-sensitivity of an area postrema (AP) neuron to glucose and amylin. Decreasing the 
glucose concentration in the superfusion solution from the standard concentration of 10 mM to 2, 4 
and 6 mM during the indicated time caused concentration-dependent decreases of the spontaneous 
discharge rate. Superfusion of amylin elicited a strong excitatory effect. Reproduced with 
permission (published in Riediger T, et al., Neurosci Lett 2002; 328:121-142). 
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Figure 6: Effect of amylin (5 µg/kg s.c.) on food intake in rats kept on different test diets (NCD = 
non-caloric diet, vanilla-flavored cellulose) for 24 h prior to injection. Bars represent group means 
± SEM (n = 12). * p < 0.05 and *** p< 0.001, significantly different from respective control 
(saline) group (paired Student t test). Modified and reproduced with permission (published in 
Michel et al., Neuroendocrinology 2007; 86:124-135). 
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